RESUMO
Rituximab is a treatment option to non-Hodg kin's diffuse large B-cell lymphoma (NHDLBCL) in advanced stage and comorbility. It is known the cardiotoxicity effect of this drug, but there is no previous report describing a complete atrioventricular block (CAVB) secundary to treatment with Rituximab. We present an elderly woman treated with monotherapy with Rituximab who experienced a CAVB after administration of the fifth dose of this drug.
Assuntos
Anticorpos Monoclonais/efeitos adversos , Antineoplásicos/efeitos adversos , Bloqueio Atrioventricular/induzido quimicamente , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Idoso de 80 Anos ou mais , Anticorpos Monoclonais Murinos , Dislipidemias/complicações , Feminino , Humanos , Linfoma Difuso de Grandes Células B/fisiopatologia , Rituximab , Osteofitose Vertebral/complicações , Acidente Vascular Cerebral/complicações , Trombose Venosa/complicaçõesRESUMO
A 75-year-old woman was diagnosed of MCD plasma cell (PC) variant with B symptoms. Diffuse lymph-node enlargement, splenomegaly and pancytopenia were detected. Induction with Rituximab was made because pancytopenia was present. Actually patient is free of disease. This is the first complete response of MCD published, VIH negative, induced with anti CD20.